BTK-CD20 – Active Featured

January 25, 20200

In Treatment-Naïve CLL Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS

At ASH 2019, they had the respect and benefit to introduce a front‑line investigation of acalabrutinib in patients with constant lymphocytic leukemia